Current Report Filing (8-k)
April 08 2019 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): April 8, 2019
TherapeuticsMD, Inc.
|
(Exact Name of Registrant as Specified in its Charter)
|
Nevada
|
|
001-00100
|
|
87-0233535
|
(State or Other
Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
6800 Broken Sound Parkway NW, Third Floor
Boca Raton, FL 33487
|
(Address of Principal Executive Office) (Zip Code)
|
Registrant's telephone number, including area
code: (561) 961-1900
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01.
|
Regulation FD Disclosure.
|
TherapeuticsMD,
Inc. is furnishing as Exhibit 99.1 to this Current Report on Form 8-K an investor presentation which will be used, in whole or
in part, and subject to modification, on April 8, 2019 and at subsequent meetings with investors or analysts.
The information
in this Current Report on Form 8-K (including the exhibit) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be
deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, nor will any of such information or exhibits be deemed incorporated by reference into
any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly
set forth by specific reference in such filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits
|
|
|
|
|
|
|
|
Exhibit
|
|
|
|
Number
|
Description
|
|
|
|
|
|
|
99.1
|
TherapeuticsMD, Inc. presentation dated April 8, 2019.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: April 8, 2019
|
THERAPEUTICSMD, INC.
|
|
|
|
By:
|
/s/
Daniel A. Cartwright
|
|
Name:
|
Daniel A. Cartwright
|
|
Title:
|
Chief Financial Officer
|
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Sep 2023 to Sep 2024